Our Clinical Trials

  • ABC-HCC Trial: A Phase IIIb, randomized, multicenter, open-label trial of Atezolizumab plus Bevacizumab versus transarterial Chemoembolization (TACE) in intermediate-stage
  • ADVANCE:  A phase II single-arm, open-label study of atezolizumab and derazantinib for patients with advanced intrahepatic cholangiocarcinoma with FGFR2 fusions/rearrangements
  • ADJUBIL A Phase II study of immunotherapy with durvalumab and tremelimumab in combination with capecitabine or without capecitabine in ADJUvant situation for BILiary tract cancer
  • AURORA: A Phase II, non-randomized, single arm, translational study of CAbozantinib for Patients with HepatocellUlaR CarcinOma (HCC) Refractory to LenvAtinib Treatment
  • CaboRise: A phase II study evaluating reduced starting dose and dose escalation of Cabozantinib as second-line therapy for advanced HCC in patients with preserved liver function
  • CONGENIAL: Comprehensive genomic profiling combined with real life data of “The German-Registry of Incidental Gallbladder Carcinoma”, the CONGENIAL analysis sub-study of the GR
  • DEMAND: The first trial of combined Atezolizumab/Bevacizumab with TACE vs. the up-front use of immunotherapy for intermediate-stage HCC
  • GAIN: A phase III study of the German Registry of Incidental Gallbladder Carcinoma Platform (GR)– The AIO/ CALGP/ ACO- GAIN-Trial – Neoadjuvant chemotherapy with gemcitabine plus cisplatin followed by radical liver resection versus immediate radical liver resection alone with or without adjuvant chemotherapy in incidentally detected gallbladder carcinoma after simple cholecystectomy or in front of radical resection of BTC (ICC/ECC)
  • IMMUCHEC: A randomized phase II trial of durvalumab and tremelIMUmab with gemcitabine or gemcitabine and cisplatin compared to gemcitabine and cisplatin in treatment-naïve patients with CHolangio- and gallbladdEr Carcinoma.
  • IMMULAB: A phase II trial of pembrolizumab in combination with radiofrequency ablation (RFA) for patients with hepatocellular carcinoma
  • IMMUNIB: A Phase II randomized, open-label study of anti-PD1 antibody in combination with Lenvatinib for advanced stage hepatocellular carcinoma (HCC)
  • IMMUTACE: A Phase II single-arm, open-label study of transarterial chemoembolization in combination with nivolumab performed for intermediate stage HCC.
  • IMMUWHY: A Phase II randomized, open-label study of durvalumab and tremelimumabin combination with Y-90 SIRT for advanced stage bilary tract cancer (BTC) 
  • IMMUWIN:  A Phase II study of immunotherapy with durvalumab and tremelimumab in combination with either Y-90 SIRT or TACE for intermediate stage HCC with pick-the-winner design
  • MONTBLANC: The first study investigating a triple CPI-based treatment with Durvalumab, Tremelimumab and Bevacizumab for advanced HCC
  • NALIRICC: A randomized phase II trial of nanoliposomal irinotecan (nal-IRI) and 5-flurouracil (5-FU) compared to 5-flurouracil in patients with cholangio- and gall-bladder carcinoma previously treated with gemcitabine- and platinum-based therapies.
  • PEARLDIFER: A Phase II study of pemigatinib after SBRT (Stereotactic Body Radiation Therapy) or other minimally invasive techniques as definitive organ preserving therapy in locally advanced intrahepatic cholangiocarcinoma (iCCA) harboring FGFR2 fusions/rearrangements
  • PERSUASION New Prospective Expanded German Registry of Incidental Gallbladder Carcinoma (PERSUASION)- a permanent platform including all kind of biliary tract cancers (BTC)
  • PLATON:  Platform for Analyzing Targetable Tumor Mutations
  • SOLARIS:  A phase-II open-label Study of pembrOlizumab and Lenvatinib in patients with Advanced stage hepatocellular carcinoma who are Refractory to atezolizumab and bevacizumab/ IO-baSed therapy